Novo Nordisk ADR (NYSE:NVO) has a beta value of 0.66 and has seen 1.68 million shares traded in the recent trading session. The company, currently valued at $226.68B, closed the recent trade at $67.34 per share which meant it gained $0.12 on the day or 0.18% during that session. The NVO stock price is -111.21% off its 52-week high price of $142.23 and 15.35% above the 52-week low of $57.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.79 million shares traded. The 3-month trading volume is 9.97 million shares.
The consensus among analysts is that Novo Nordisk ADR (NVO) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
Novo Nordisk ADR (NYSE:NVO) trade information
Sporting 0.18% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the NVO stock price touched $67.34 or saw a rise of 6.15%. Year-to-date, Novo Nordisk ADR shares have moved -52.60%, while the 5-day performance has seen it change -3.37%. Over the past 30 days, the shares of Novo Nordisk ADR (NYSE:NVO) have changed -15.65%. Short interest in the company has seen 26.61 million shares shorted with days to cover at 2.65.
Wall Street analysts have a consensus price target for the stock at $158, which means that the shares’ value could jump 57.38% from the levels at last check today.. The projected low price target is $156.0 while the price target rests at a high of $160.0. In that case, then, we find that the latest price level in today’s session is -137.6% off the targeted high while a plunge would see the stock gain -131.66% from the levels at last check today..
Novo Nordisk ADR (NVO) estimates and forecasts
The company’s shares have lost -20.42% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 21.74% over the past 5 years. Earnings growth for 2025 is a modest 28.82% while over the next 5 years, the company’s earnings are expected to increase by 18.63%.
NVO Dividends
Novo Nordisk ADR is expected to release its next earnings report on 2025-May-07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.66 at a share yield of 2.47%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 1.46%.
Novo Nordisk ADR (NYSE:NVO)’s Major holders
Insiders own 0.01% of the company shares, while shares held by institutions stand at 9.85% with a share float percentage of 9.85%. Investors are also buoyed by the number of investors in a company, with Novo Nordisk ADR having a total of 1789.0 institutions that hold shares in the company. The top two institutional holders are JENNISON ASSOCIATES LLC with over 21.22 million shares worth more than $3.03 billion. As of 2024-06-30, JENNISON ASSOCIATES LLC held 0.476% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 19.49 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.78 billion and represent 0.4373% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are HARBOR FUNDS-Harbor Capital Appreciation Fund and Bridge Builder Trust-Bridge Builder Large Cap Growth Fund . As of Apr 30, 2025 , the former fund manager holds about 0.12% shares in the company for having 4.11 shares of worth $276.39 million while later fund manager owns 3.37 shares of worth $226.76 million as of Mar 31, 2025 , which makes it owner of about 0.10% of company’s outstanding stock.
